Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2012 1
2013 1
2014 1
2015 1
2017 1
2020 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Hammond D, et al. Among authors: pierce sr. Blood Cancer J. 2023 Sep 21;13(1):148. doi: 10.1038/s41408-023-00915-6. Blood Cancer J. 2023. PMID: 37735426 Free PMC article. No abstract available.
Clinical value of event-free survival in acute myeloid leukemia.
Maiti A, Kantarjian HM, Popat V, Borthakur G, Garcia-Manero G, Konopleva MY, DiNardo CD, Verstovsek S, Andreeff M, Kadia TM, Ajufo HO, Goswamy RV, Blanco C, Velasquez M, Daver NG, Pemmaraju N, Pierce SR, Wierda WG, Kornblau SM, Ravandi F, Cortes JE. Maiti A, et al. Among authors: pierce sr. Blood Adv. 2020 Apr 28;4(8):1690-1699. doi: 10.1182/bloodadvances.2019001150. Blood Adv. 2020. PMID: 32330243 Free PMC article.
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Montalban-Bravo G, et al. Among authors: pierce sr. Blood Adv. 2020 Feb 11;4(3):482-495. doi: 10.1182/bloodadvances.2019001101. Blood Adv. 2020. PMID: 32027746 Free PMC article.
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Lachowiez CA, et al. Among authors: pierce sr. Blood Adv. 2020 Apr 14;4(7):1311-1320. doi: 10.1182/bloodadvances.2019001267. Blood Adv. 2020. PMID: 32251497 Free PMC article.
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM. Boddu P, et al. Among authors: pierce sr. Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25. Blood Adv. 2017. PMID: 29296774 Free PMC article.
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia.
Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Benton CB, et al. Among authors: pierce sr. Br J Haematol. 2014 Nov;167(3):356-65. doi: 10.1111/bjh.13050. Epub 2014 Jul 26. Br J Haematol. 2014. PMID: 25066676 Free PMC article. Clinical Trial.
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, O'Brien S, Estrov Z, Borthakur G, Thomas D, Pierce SR, Brandt M, Byrd A, Bekele BN, Pratz K, Luthra R, Levis M, Andreeff M, Kantarjian HM. Ravandi F, et al. Among authors: pierce sr. J Clin Oncol. 2010 Apr 10;28(11):1856-62. doi: 10.1200/JCO.2009.25.4888. Epub 2010 Mar 8. J Clin Oncol. 2010. PMID: 20212254 Free PMC article. Clinical Trial.
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S. Badar T, et al. Among authors: pierce sr. Leuk Res. 2015 Sep;39(9):950-6. doi: 10.1016/j.leukres.2015.06.001. Epub 2015 Jun 11. Leuk Res. 2015. PMID: 26183878 Free PMC article.
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH. Walter RB, et al. Among authors: pierce sr. Blood. 2013 Mar 28;121(13):2424-31. doi: 10.1182/blood-2012-10-462440. Epub 2013 Jan 16. Blood. 2013. PMID: 23325837 Free PMC article.
11 results